Please try another search
Cingulate Inc., a biopharmaceutical company, develops pharmaceutical products using delivery platform technology for the treatment of attention deficit/hyperactivity disorder (ADHD) and anxiety in the United States. The company’s lead product candidate is CTx-1301 (dexmethylphenidate), which is in Phase 3 clinical trials. It also develops CTx-2103 (buspirone) that is in a formulation stage for the treatment of anxiety and mental health disorders; and plans to initiate the clinical plan for CTx-1302 (dextroamphetamine) to treat ADHD in children, adolescents, and adults. Cingulate Inc. was founded in 2012 and is headquartered in Kansas City, Kansas.
| Name | Age | Since | Title |
|---|---|---|---|
| John A. Roberts | 66 | 2024 | Independent Chairman of the Board |
| Declan Quinn | - | - | Member of Scientific Advisory Board |
| Peter J. Werth | 86 | 2018 | Director |
| Dinohra Munoz-Silva | - | - | Member of Scientific Advisory Board |
| Brian D. Barash | - | - | Member of Scientific Advisory Board |
| Andrew J. Cutler | - | - | Member of Scientific Advisory Board |
| Ann Childress | - | - | Member of Scientific Advisory Board |
| Alice Mao | - | - | Member of Scientific Advisory Board |
| John S. Markowitz | - | - | Member of Scientific Advisory Board |
| Laurence L. Greenhill | - | - | Member of Scientific Advisory Board |
| Sharon B. Wigal | - | - | Member of Scientific Advisory Board |
| Jeffrey Newcorn | - | - | Member of Scientific Advisory Board |
| Jeffrey S. Ervin | 47 | 2024 | Independent Director |
| Bryan Jay Lawrence | 59 | 2024 | Independent Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review